Open-Label Multicentre Study on Efficacy and Safety of Oral Quetiapine (Seroquel XR) in Adults With Schizophrenia.

Trial Profile

Open-Label Multicentre Study on Efficacy and Safety of Oral Quetiapine (Seroquel XR) in Adults With Schizophrenia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2012

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 19 Jul 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Jan 2010 Planned end date changed from 1 Mar 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.
    • 02 Mar 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top